Alnylam Pharmaceuticals, Inc.
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
Last updated:
Abstract:
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.
Status:
Application
Type:
Utility
Filling date:
4 Jun 2020
Issue date:
25 Mar 2021